Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing

This publication has 50 references indexed in Scilit:

• Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine‐maintained intravenous heroin abusers
  Addiction, 2010
• Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
  The American Journal of Drug and Alcohol Abuse, 2009
• Buprenorphine injection in Melbourne, Australia—an update
  Drug and Alcohol Review, 2008
• Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone
  Drug and Alcohol Dependence, 2007
• Mechanisms of Prescription Drug Diversion Among Drug-Involved Club- and Street-Based Populations
  Pain Medicine, 2007
• History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs
  Drug and Alcohol Dependence, 2006
• Buprenorphine
  Clinical Pharmacokinetics, 2005
• Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets
  Drug and Alcohol Review, 2003
• Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin Abusers
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand
  Drug and Alcohol Dependence, 1993